Randomised trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML

Описание к видео Randomised trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML

Dr Mark Levis speaks to ecancer at EHA 2023 about a randomised trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML.

He explains that results show that there is an apparent benefit of gilteritinib but that it did not reach statistical significance.

Dr Levis explains that they made an assumption that not everyone would benefit but that they were intending to find out who would benefit. Those who showed MRD around the time of transplant showed best benefit.

Комментарии

Информация по комментариям в разработке

Похожие видео